Aptose Biosciences Valuation
| APTO Stock | USD 3.95 0.14 3.67% |
At this time, the firm appears to be overvalued. Aptose Biosciences shows a prevailing Real Value of $3.66 per share. The current price of the firm is $3.95. Our model approximates the value of Aptose Biosciences from analyzing the firm fundamentals such as Shares Owned By Insiders of 5.71 %, current valuation of 631.52 K, and Return On Equity of -6.94 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Aptose Biosciences' price fluctuation is dangerous at this time. Calculation of the real value of Aptose Biosciences is based on 3 months time horizon. Increasing Aptose Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Aptose Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Aptose Stock. However, Aptose Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.95 | Real 3.66 | Hype 3.81 | Naive 5.27 |
The intrinsic value of Aptose Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Aptose Biosciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Aptose Biosciences helps investors to forecast how Aptose stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Aptose Biosciences more accurately as focusing exclusively on Aptose Biosciences' fundamentals will not take into account other important factors: Aptose Biosciences Total Value Analysis
Aptose Biosciences is presently anticipated to have valuation of 631.52 K with market capitalization of 8.19 M, debt of 1.01 M, and cash on hands of 62.41 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Aptose Biosciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
631.52 K | 8.19 M | 1.01 M | 62.41 M |
Aptose Biosciences Asset Utilization
One of the ways to look at asset utilization of Aptose is to check how much profit was generated for every dollar of assets it reports. Aptose Biosciences shows a negative utilization of assets of -1.42 percent, losing $0.0142 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Aptose Biosciences shows how discouraging it operates for each dollar spent on its assets.Aptose Biosciences Ownership Allocation
Aptose Biosciences shows 5.71 percent of its outstanding shares held by insiders and 7.79 percent owned by other corporate entities.Aptose Biosciences Profitability Analysis
Net Loss for the year was (51.21 M) with profit before overhead, payroll, taxes, and interest of 0.About Aptose Biosciences Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Aptose Biosciences. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Aptose Biosciences based exclusively on its fundamental and basic technical indicators. By analyzing Aptose Biosciences's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Aptose Biosciences's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Aptose Biosciences. We calculate exposure to Aptose Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Aptose Biosciences's related companies.Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada. Aptose Bioscns operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people.
Aptose Biosciences Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 6.8 M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptose Biosciences. If investors know Aptose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptose Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Aptose Biosciences is measured differently than its book value, which is the value of Aptose that is recorded on the company's balance sheet. Investors also form their own opinion of Aptose Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Aptose Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptose Biosciences' market value can be influenced by many factors that don't directly affect Aptose Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptose Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptose Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptose Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.